FIA
AVEO

FNY Investment Advisers’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

FNY Investment Advisers’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-80
Closed -$2K – 1177
2018
Q3 		$2K Buy
+80
New +$2.06K ﹤0.01% 751

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

FNY Investment Advisers's AVEO Position: Q4 2018 in Review

FNY Investment Advisers sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 80 shares — an estimated $2K sold.

FNY Investment Advisers first reported a position in AVEO in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

  • FNY Investment Advisers reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 80 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2K.
  • FNY Investment Advisers first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • FNY Investment Advisers's AVEO Pharmaceuticals, Inc. position peaked at $2K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.